Publications

  1. Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928 Epub 2024 Aug 13
    View PubMed
  2. Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024 Jun 10; 42 (17):2061-2070 Epub 2024 Mar 26
    View PubMed
  3. Kowalchuk RO, Mullikin TC, Spears GM, Johnson-Tesch BA, Rose PS, Siontis BL, Kun Kim D, Costello BA, Morris JM, Gao RW, Shiraishi S, Lucido JJ, Olivier KR, Owen D, Stish BJ, Waddle MR, Laack NN, Park SS, Brown PD, Merrell KW. Assessment of minimum target dose as a predictor of local failure after spine SBRT. Radiother Oncol. 2024 Jun; 195:110260 Epub 2024 Mar 27
    View PubMed
  4. Joyce DD, Sharma V, Wymer KM, Moriarty JP, Borah BJ, Walia A, Costello BA, Pagliaro LC, Daneshmand S, Leibovich BC, Boorjian SA. Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma. J Natl Cancer Inst. 2024 Mar 7; 116 (3):468-475
    View PubMed
  5. Dasari S, McCarthy MR, Wojcik AA, Pitel BA, Samaddar A, Tekin B, Whaley RD, Raghunathan A, Hernandez LH, Jimenez RE, Stish BJ, Thompson RH, Leibovich BC, Boorjian SA, Jeffrey Karnes R, Childs DS, Quevedo JF, Kwon ED, Pagliaro LC, Costello BA, Halling KC, Cheville JC, Kipp BR, Gupta S. Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients. Prostate Cancer Prostatic Dis. 2024 Feb 27. [Epub ahead of print]
    View PubMed
  6. Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. NCCN Guidelines(R) Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024 Feb; 22 (1):4-16
    View PubMed
  7. Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42 (1):127-135 Epub 2024 Jan 25
    View PubMed
  8. Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. Kidney cancer, version 2.2024: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network. 2024 Feb; 22 (1):5-16
  9. Harper KC, Atwell TD, Kassmeyer BA, Jang S, Potretzke AM, Costello BA, Welch TL, Boorjian SA, Welch BT. Percutaneous Image Guided Cryoablation of Adrenal Metastases From Renal Cell Carcinoma: A Single Institution Review. Urology. 2024 Jan; 183:141-146. Epub 2023 Oct 11.
    View PubMed
  10. Pessoa RR, Nabavizadeh R, Quevedo F, Joyce DD, Lohse CM, Sharma V, Costello BA, Boorjian SA, Thompson RH, Leibovich BC, Cheville JC. The Impact of Metastasis Histopathology on Oncologic Outcomes for Patients With Surgically Resected Metastatic Renal Cell Carcinoma. J Urol. 2023 Oct; 210 (4):611-618 Epub 2023 June 20
    View PubMed
  11. Rodrigues Pessoa R, Zhang H, Zganjar A, Nabavizadeh R, Packiam VT, Lohse CM, Cheville JC, Pagliaro LC, Costello BA, Boorjian SA, Thompson RH, Lucien F, Dong H, Leibovich BC. Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery. Urol Oncol. 2023 Sep; 41 (9):393.e1-393.e7 Epub 2023 July 04
    View PubMed
  12. Eule CJ, Hu J, Al-Saad S, Collier K, Boland P, Lewis AR, McKay RR, Narayan V, Bosse D, Mortazavi A, Rose TL, Costello BA, Bryce AH, Lam ET. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. Clin Genitourin Cancer. 2023 Aug; 21 (4):483-490 Epub 2023 Apr 24
    View PubMed
  13. Soekojo CY, Yin J, Kline J, Lazaryan A, Bartlett N, Geethakumari PR, Awan F, Karmali R, Hernandez-Ilizaliturri FJ, Shune L, Lansigan F, Reeder C, Diefenbach C, Sharon E, Mikula E, Strand C, Postovalova E, Kotlov N, Zornikova K, Bagaev A, Fowler N, Whitaker KR, Ferre RL, Costello BA, Yang ZZ, Tang X, Ansell SM, Villasboas JC. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:592-594
    View PubMed
  14. Lewis AR, Costello BA, Quevedo F, Pagliaro LC, Sanhueza C, Weinshilboum RM, Kalari KR, Wang L, Kohli M, Tan W, Giridhar KV. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2023 May; 83 (7):649-655 Epub 2023 Mar 16
    View PubMed
  15. Mahmoud AM, Nabavizadeh R, Rodrigues Pessoa R, Garg I, Orme J, Costello BA, Cheville J, Lucien F. Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities. Oncologist. 2023 Apr 6; 28 (4):297-308
    View PubMed
  16. Kowalchuk RO, Mullikin TC, Florez M, De BS, Spears GM, Rose PS, Siontis BL, Kim DK, Costello BA, Morris JM, Marion JT, Johnson-Tesch BA, Gao RW, Shiraishi S, Lucido JJ, Trifiletti DM, Olivier KR, Owen D, Stish BJ, Waddle MR, Laack NN, Park SS, Brown PD, Ghia AJ, Merrell KW. Development and validation of a recursive partitioning analysis-based pretreatment decision-making tool identifying ideal candidates for spine stereotactic body radiation therapy. Cancer. 2023 Mar 15; 129(6):956-965. Epub 2022 Dec 26.
    View PubMed
  17. Britton CJ, Andrews JR, Wallis CJD, Sharma V, Leibovich BC, Thompson RH, Boorjian SA, Bhindi B, Costello BA. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis. Urol Oncol. 2023 Mar; 41 (3):125-136 Epub 2022 Oct 28
    View PubMed
  18. Lyon TD, Roussel E, Sharma V, Carames G, Lohse CM, Costello BA, Boorjian SA, Thompson RH, Joniau S, Albersen M, Leibovich BC. International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma. Eur Urol Oncol. 2023 Feb; 6 (1):76-83 Epub 2022 Dec 09
    View PubMed
  19. Gottlich HC, Nabavizadeh R, Dumbrava M, Rodrigues Pessoa R, Mahmoud AM, Garg I, Orme J, Costello BA, Cheville J, Lucien F. Emerging antibody-drug conjugate therapies and targets for metastatic renal cell carcinoma. Kidney Cancer. 2023; 7 (1):161-72
  20. Kowalchuk R, Mullikin TC, Breen W, Gits HC, Florez M, De B, Harmsen WS, Rose PS, Siontis BL, Costello BA, Morris JM, Lucido JJ, Olivier KR, Stish B, Laack NN, Park S, Owen D, Ghia AJ, Brown PD, Merrell KW. Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy. Front Oncol. 2023; 13:1095170 Epub 2023 Mar 27
    View PubMed
  21. Sharma V, Wymer KM, Joyce DD, Moriarty J, Khanna A, Borah BJ, Thompson RH, Costello BA, Leibovich BC, Boorjian SA. Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov Model. J Urol. 2023 Jan; 209 (1):89-98 Epub 2022 Sept 06
    View PubMed
  22. Joyce DD, Wymer KM, Sharma V, Moriarty JP, Borah BJ, Geynisman DM, Plimack ER, Costello BA, Pagliaro LC, Boorjian SA. Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data. Cancer. 2022 Dec 15; 128 (24):4194-4202 Epub 2022 Oct 17
    View PubMed
  23. Chinniah S, Stish B, Costello BA, Pagliaro L, Childs D, Quevedo F, Lucien F, Bryce A, Park SS, Orme JJ. Radiation Therapy in Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 Nov 15; 114 (4):684-692 Epub 2022 July 22
    View PubMed
  24. Britton CJ, Andrews JR, Wallis , C, Sharma V, Leibovich BC, Thompson R, Boorjian SA, Bhindi , B, Costello BA. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis Urologic Oncology. 2022; 41(3):125-36.
  25. Velez MG, Kosiorek HE, Egan JB, McNatty AL, Riaz IB, Hwang SR, Stewart GA, Ho TH, Moore CN, Singh P, Sharpsten RK, Costello BA, Bryce AH. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep; 25 (3):479-483 Epub 2021 July 22
    View PubMed
  26. Huang M, Wen A, He H, Wang L, Liu S, Wang Y, Zong N, Yu Y, Prigge JE, Costello BA, Shah ND, Ting HH, Doubeni C, Fan JW, Liu H, Patten CA. Midwest rural-urban disparities in use of patient online services for COVID-19. J Rural Health. 2022 Sep; 38 (4):908-915 Epub 2022 Mar 08
    View PubMed
  27. Kowalchuk RO, Mullikin TC, Harmsen WS, Rose PS, Siontis BL, Kim DK, Costello BA, Morris JM, Marion JT, Johnson-Tesch BA, Gao RW, Shiraishi S, Lucido JJ, Olivier KR, Owen D, Stish BJ, Laack NN, Park SS, Brown PD, Merrell KW. Development and internal validation of a recursive partitioning analysis-based model predictive of pain flare incidence after spine stereotactic body radiation therapy. Practical Radiation Oncology. 2022 Jul-aug; 12 (4):E269-77
  28. Mahmoud AM, Frank I, Orme JJ, Lavoie RR, Thapa P, Costello BA, Cheville JC, Gupta S, Dong H, Lucien F. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. BMC Urol. 2022 Jun 24; 22 (1):90 Epub 2022 June 24
    View PubMed
  29. Psutka SP, Gulati R, Jewett MAS, Fadaak K, Finelli A, Legere L, Morgan TM, Pierorazio PM, Allaf ME, Herrin J, Lohse CM, Houston Thompson R, Boorjian SA, Atwell TD, Schmit GD, Costello BA, Shah ND, Leibovich BC. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol. 2022 Jun; 81 (6):576-585 Epub 2021 Nov 30
    View PubMed
  30. Huang M, Khurana A, Mastorakos G, Wen A, He H, Wang L, Liu S, Wang Y, Zong N, Prigge J, Costello B, Shah N, Ting H, Fan J, Patten C, Liu H. Patient Portal Messaging for Asynchronous Virtual Care During the COVID-19 Pandemic: Retrospective Analysis. JMIR Hum Factors. 2022 May 5; 9 (2):e35187 Epub 2022 May 05
    View PubMed
  31. Stewart GA, Breen WG, Stish BJ, Mullikin TC, Park SS, Olivier KR, Costello BA. Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era. Clin Genitourin Cancer. 2022 Apr; 20 (2):107-113 Epub 2021 Nov 10
    View PubMed
  32. Andrews JR, Lohse CM, Boorjian SA, Leibovich BC, Thompson H, Costello BA, Bhindi B. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. Urol Oncol. 2022 Apr; 40 (4):166.e1-166.e8 Epub 2022 Feb 13
    View PubMed
  33. Orme JJ, Pagliaro LC, Quevedo JF, Park SS, Costello BA. Rational Second-Generation Antiandrogen Use in Prostate Cancer. Oncologist. 2022 Mar 4; 27 (2):110-124
    View PubMed
  34. Kowalchuk RO, Johnson-Tesch BA, Marion JT, Mullikin TC, Harmsen WS, Rose PS, Siontis BL, Kim DK, Costello BA, Morris JM, Gao RW, Shiraishi S, Lucido JJ, Sio TT, Trifiletti DM, Olivier KR, Owen D, Stish BJ, Waddle MR, Laack NN, Park SS, Brown PD, Merrell KW. Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal Metastases. JAMA Oncol. 2022 Mar 01; 8(3):412-419.
    View PubMed
  35. Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2022 Feb; 40 (1):115-123 Epub 2021 Sept 13
    View PubMed
  36. Costello BA, Bhavsar NA, Zakharia Y, Pal SK, Vaishampayan U, Jim H, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Mardekian J, Borham A, George DJ, Harrison MR. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer. 2022 Feb; 20(1):1-10. Epub 2021 Jul 10.
    View PubMed
  37. Huang M, Fan J, Prigge J, Shah ND, Costello BA, Yao L. Characterizing Patient-Clinician Communication in Secure Medical Messages: Retrospective Study. J Med Internet Res. 2022 Jan 11; 24 (1):e17273
    View PubMed
  38. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney cancer, version 3.2022. Journal of the National Comprehensive Cancer Network. 2022 Jan; 20 (1):71-90
  39. Xie Z, Yadav S, Lohse CM, Cheville JC, Pagliaro LC, Shah PH, Boorjian SA, Thompson H, Leibovich BC, Costello BA. Collecting duct carcinoma: A single-institution retrospective study. Urol Oncol. 2022 Jan; 40 (1):13.e9-13.e18 Epub 2021 Nov 06
    View PubMed
  40. Kumar SK, Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Elsedawy N, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Jan; 20 (1):71-90
    View PubMed
  41. Kowalchuk RO, Mullikin TC, Harmsen WS, Rose PS, Siontis BL, Kim DK, Costello BA, Morris JM, Marion JT, Johnson-Tesch BA, Gao RW, Shiraishi S, Lucido JJ, Olivier KR, Owen D, Stish BJ, Laack NN, Park SS, Brown PD, Merrell KW. Development and Internal Validation of a Recursive Partitioning Analysis-Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation Therapy. Pract Radiat Oncol. 2022 Jul-Aug; 12(4):e269-e277. Epub 2022 Feb 10.
    View PubMed
  42. Chinniah S, Stish B, Costello BA, Pagliaro L, Childs D, Quevedo F, Lucien F, Bryce A, Park SS, Orme JJ. Radiation therapy in oligometastatic prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2022; 114 (4):684-92
  43. Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, Tryggestad EJ, Bold MS, Pagliaro LC, Choo CR, Brinkmann DH, Iott MJ, Davis BJ, Quevedo JF, Harmsen WS, Costello BA, Johnson GB, Nathan MA, Olivier KR, Pisansky TM, Kwon ED, Dong H, Park SS. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in (11)C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 Dec 1; 27 (23):6376-6383 Epub 2021 Sept 30
    View PubMed
  44. Riaz IB, He H, Ryu AJ, Siddiqi R, Naqvi SAA, Yao Y, Husnain M, Narasimhulu DM, Mathew J, Sipra QUAR, Vandvik PO, Joseph RW, Liu H, Wang Z, Herasevich V, Singh P, Hussain SA, Ho TH, Bryce AH, Pagliaro LC, Murad MH, Costello BA. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. Eur Urol. 2021 Dec; 80 (6):712-723 Epub 2021 Apr 03
    View PubMed
  45. Zhu M, Costello BA, Yin J, Pettinger AM, Strosberg JR, Erlichman C, Hobday TJ. Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors. Pancreas. 2021 Nov-Dec 01; 50(10):1435-1439.
    View PubMed
  46. Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L, Lafky JM, Smith E, Pachman D, Staff N, Ma C, Loprinzi CL, Costello BA. Correction to: Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer. 2021 Nov; 29 (11):7129-7130
    View PubMed
  47. Childs DS, Quevedo JF, Costello BA, Pagliaro LC. Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series. Anticancer Drugs. 2021 Oct 1; 32 (9):986-990
    View PubMed
  48. Wee CE, Costello BA, Orme JJ, Quevedo JF, Pagliaro LC. Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience. Prostate. 2021 Sep; 81 (13):938-943 Epub 2021 July 12
    View PubMed
  49. Harrison MR, Costello BA, Bhavsar NA, Vaishampayan U, Pal SK, Zakharia Y, Jim HSL, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Inman BA, Mardekian J, Borham A, George DJ. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer. 2021 Jul 01; 127(13):2204-2212. Epub 2021 Mar 25.
    View PubMed
  50. Freitag CE, Sukov WR, Bryce AH, Berg JV, Vanderbilt CM, Shen W, Smadbeck JB, Greipp PT, Ketterling RP, Jenkins RB, Herrera-Hernandez L, Costello BA, Thompson RH, Boorjian SA, Leibovich BC, Jimenez RE, Murphy SJ, Vasmatzis G, Cheville JC, Gupta S. Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Hum Pathol. 2021 Jun; 112:20-34 Epub 2021 Mar 31
    View PubMed
  51. Polavaram NS, Dutta S, Islam R, Bag AK, Roy S, Poitz D, Karnes J, Hofbauer LC, Kohli M, Costello BA, Jimenez R, Batra SK, Teply BA, Muders MH, Datta K. Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. Bone Res. 2021 May 14; 9 (1):24
    View PubMed
  52. Dubey D, Kryzer T, Guo Y, Clarkson B, Cheville JC, Costello BA, Leibovich BC, Algeciras-Schimnich A, Lucchinnetti C, Hammami MB, Knight AM, Howe C, Lennon VA, McKeon A, Pittock SJ. Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. Ann Neurol. 2021 May; 89(5):1001-1010. Epub 2021 Feb 28.
    View PubMed
  53. Grach SL, Saliba AN, Costello BA. 40-Year-Old Man With Left Leg Swelling and Abdominal Pain. Mayo Clin Proc. 2021 Mar; 96 (3):782-787
    View PubMed
  54. Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L, Lafky JM, Smith E, Pachman D, Staff N, Ma C, Loprinzi CL, Costello BA. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer. 2021 Feb; 29 (2):833-840 Epub 2020 June 04
    View PubMed
  55. Haddad TC, Blegen RN, Prigge JE, Cox DL, Anthony GS, Leak MA, Channer DD, Underwood PY, Williams RD, Hofschulte RD, Christopherson LA, Coffey JD, TerKonda SP, Yiannias JA, Costello BA, Russi CS, Colby CE, Ommen SR, Demaerschalk BM. A Scalable Framework for Telehealth: The Mayo Clinic Center for Connected Care Response to the COVID-19 Pandemic. Telemed Rep. 2021; 2 (1):78-87 Epub 2021 Feb 24
    View PubMed
  56. Mehra NS, Ho TP, Herrera Hernandez L, Quevedo JF, Costello BA, Pagliaro LC. Penile cancer with visceral metastasis and p16/human papillomavirus positivity: An unusual case of long-term survival. Urol Case Rep. 2020 Nov; 33:101278 Epub 2020 May 24
    View PubMed
  57. Eckel-Passow JE, Yan H, Kosel ML, Serie D, Decker PA, Jenkins RB, Costello B, Leibovich B, Ho TH, Parker A. 8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. BMC Urol. 2020 Oct 29; 20 (1):173
    View PubMed
  58. Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, Agarwal N, Zakharia Y, Costello BA, McKay RR, Narayan V, Alva A, McGregor BA, Gao X, McDermott DF, Choueiri TK. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncol. 2020 Oct 1; 6 (10):1606-1610
    View PubMed
  59. Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw. 2020 Sep; 18 (9):1160-1170
    View PubMed
  60. Eckel-Passow JE, Ho TH, Serie DJ, Cheville JC, Houston Thompson R, Costello BA, Dong H, Kwon ED, Leibovich BC, Parker AS. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. Cancer Med. 2020 Feb; 9 (3):1152-1160 Epub 2019 Dec 12
    View PubMed
  61. Packiam VT, Tyson Ii MD, Tsivian M, Lohse CM, Boorjian SA, Cheville JC, Costello BA, Leibovich BC, Thompson RH. The association of anxiety and depression with perioperative and oncologic outcomes among patients with clear cell renal cell carcinoma undergoing nephrectomy. Urol Oncol. 2020 Feb; 38 (2):41.e19-41.e27 Epub 2019 Nov 21
    View PubMed
  62. Lyon TD, Thompson RH, Shah PH, Lohse CM, Boorjian SA, Costello BA, Cheville JC, Leibovich BC. Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era. J Urol. 2020 Feb; 203 (2):275-282 Epub 2019 Aug 08
    View PubMed
  63. Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, Hammond LJ, Zuccarino-Catania G, CGC. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw. 2019 Nov 1; 17 (11):1278-1285
    View PubMed
  64. Bryce AH, Egan JB, Smadbeck JB, Johnson SH, Murphy SJ, Harris FR, Halling GC, Terra SBSP, Cheville J, Pagliaro L, Leibovich B, Costello BA, Vasmatzis G. Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing. Sci Rep. 2019 Mar 5; 9 (1):3586 Epub 2019 Mar 05
    View PubMed
  65. Gershman B, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma. Eur Urol. 2018 Dec; 74 (6):825-832 Epub 2018 Sept 24
    View PubMed
  66. Lyon TD, Gershman B, Shah PH, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. Urol Oncol. 2018 Nov; 36 (11):499.e1-499.e7 Epub 2018 Sept 15
    View PubMed
  67. Bhindi B, Thompson RH, Lohse CM, Mason RJ, Frank I, Costello BA, Potretzke AM, Hartman RP, Potretzke TA, Boorjian SA, Cheville JC, Leibovich BC. The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. Eur Urol. 2018 Oct; 74 (4):489-497 Epub 2018 July 13
    View PubMed
  68. Bhindi B, Habermann EB, Mason RJ, Costello BA, Pagliaro LC, Thompson RH, Leibovich BC, Boorjian SA. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. J Urol. 2018 Sep; 200 (3):528-534 Epub 2018 Mar 21
    View PubMed
  69. Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018 Sep; 21 (3):431-437 Epub 2018 June 01
    View PubMed
  70. Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 May 10; 36 (14):1412-1418 Epub 2018 Mar 27
    View PubMed
  71. Gershman B, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-based Analysis. Eur Urol. 2018 Mar; 73 (3):469-475 Epub 2017 Nov 11
    View PubMed
  72. Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018 Feb 01; 29(2):352-360.
    View PubMed
  73. Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018 Jan 11; 131 (2):182-190 Epub 2017 Oct 26
    View PubMed
  74. Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M. Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. Int J Mol Sci. 2017 Nov 3; 18 (11) Epub 2017 Nov 03
    View PubMed
  75. Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC, Costello BA, Pagliaro LC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017 Nov; 72 (5):660-664 Epub 2017 May 22
    View PubMed
  76. Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res. 2017 Aug 15; 23 (16):4704-4715 Epub 2017 May 04
    View PubMed
  77. Shenoy N, Dronca R, Quevedo F, Boorjian SA, Cheville J, Costello B, Kohli M, Witzig T, Pagliaro L. Low hypoxia inducible factor-1alpha (HIF-1alpha) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity? Chin J Cancer Res. 2017 Aug; 29 (4):374-378
    View PubMed
  78. Gershman B, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. Eur Urol. 2017 Aug; 72 (2):300-306 Epub 2017 Jan 13
    View PubMed
  79. Gupta S, Johnson SH, Vasmatzis G, Porath B, Rustin JG, Rao P, Costello BA, Leibovich BC, Thompson RH, Cheville JC, Sukov WR. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Mod Pathol. 2017 Jul; 30 (7):998-1012 Epub 2017 Mar 24
    View PubMed
  80. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jun; 15 (6):804-834
    View PubMed
  81. Gershman B, Thompson RH, Moreira DM, Boorjian SA, Tollefson MK, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. Eur Urol. 2017 Apr; 71 (4):560-567 Epub 2016 Sept 24
    View PubMed
  82. Gershman B, Thompson RH, Moreira DM, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. J Urol. 2017 Mar; 197 (3 Pt 1):574-579 Epub 2016 Sept 20
    View PubMed
  83. Zhang BY, Riska SM, Mahoney DW, Costello BA, Kohli R, Quevedo JF, Cerhan JR, Kohli M. Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer. BJU Int. 2017 Mar; 119 (3):489-495 Epub 2016 Aug 06
    View PubMed
  84. Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, Boorjian SA, Costello BA, Thompson RH, Leibovich BC. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. J Urol. 2017 Jan; 197 (1):44-49 Epub 2016 July 26
    View PubMed
  85. Psutka SP, Heidenreich M, Boorjian SA, Bailey GC, Cheville JC, Stewart-Merrill SB, Lohse CM, Atwell TD, Costello BA, Leibovich BC, Thompson RH. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. BJU Int. 2017 Jan; 119 (1):116-127 Epub 2016 Aug 31
    View PubMed
  86. Joyce DD, Psutka SP, Groeschl RT, Thompson RH, Boorjian SA, Cheville JC, Stewart-Merrill SB, Lohse CM, Costello BA, Que FG, Leibovich BC. Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. Urology. 2017 Jan; 99:155-161 Epub 2016 Aug 17
    View PubMed
  87. Gershman B, Takahashi N, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model. BJU Int. 2016 Nov; 118 (5):742-749 Epub 2016 Feb 23
    View PubMed
  88. Psutka SP, Cheville JC, Costello BA, Stewart-Merrill SB, Lohse CM, Leibovich BC, Boorjian SA, Thompson RH. Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma. Urology. 2016 Oct; 96:106-113 Epub 2016 July 21
    View PubMed
  89. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Costello BA, Thompson RH, Stewart-Merrill SB, Lohse CM, Cheville JC, Leibovich BC, Tollefson MK. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. J Urol. 2016 Feb; 195 (2):270-6 Epub 2015 Aug 18
    View PubMed
  90. Gershman B, Moreira DM, Boorjian SA, Lohse CM, Cheville JC, Costello BA, Leibovich BC, Thompson RH. Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. Eur Urol. 2016 Jan; 69 (1):84-91 Epub 2015 June 01
    View PubMed
  91. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, METEOR Investigators . Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5; 373 (19):1814-23 Epub 2015 Sept 25
    View PubMed
  92. Gupta S, Thompson RH, Boorjian SA, Thapa P, Hernandez LP, Jimenez RE, Costello BA, Frank I, Cheville JC. High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. Pathology. 2015 Oct; 47 (6):533-42
    View PubMed
  93. Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T. A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2015 Aug 1; 21 (15):3420-7 Epub 2015 Mar 18
    View PubMed
  94. Zhang BY, Cheville JC, Thompson RH, Lohse CM, Boorjian SA, Leibovich BC, Costello BA. Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma. Eur Urol. 2015 Jul; 68 (1):5-7 Epub 2015 Jan 28
    View PubMed
  95. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13 (6):772-99
    View PubMed
  96. Smaldone MC, Handorf E, Kim SP, Thompson RH, Costello BA, Corcoran AT, Wong YN, Uzzo RG, Leibovich BC, Kutikov A, Boorjian SA. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database. J Urol. 2015 Apr; 193 (4):1108-13 Epub 2014 Oct 23
    View PubMed
  97. Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC, Costello BA. A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int. 2015 Mar; 115 (3):405-11 Epub 2014 Oct 19
    View PubMed
  98. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R, National comprehensive cancer network. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb; 13 (2):151-9
    View PubMed
  99. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67 (1):33-41 Epub 2014 Aug 14
    View PubMed
  100. Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, Lohse CM, Kohli M, Costello BA, Olivier KR, Thompson RH, Boorjian SA, Atwell TD. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol. 2014 Aug; 192 (2):357-63 Epub 2014 Mar 12
    View PubMed
  101. Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C, Alberts SR. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs. 2014 Aug; 32 (4):710-6 Epub 2014 Apr 18
    View PubMed
  102. Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, Cheville JC. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014 May; 27 (5):758-64 Epub 2013 Nov 01
    View PubMed
  103. Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, Dronca R, Costello B, Frank I. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int. 2014 May; 113(5b):E17-21. Epub 2013 Sep 05.
    View PubMed
  104. Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, Pisansky TM. Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2014 Jan; 32 (1):24.e1-6 Epub 2013 Mar 11
    View PubMed
  105. Patel K, Foster NR, Farrell A, Le-Lindqwister NA, Mathew J, Costello B, Reynolds J, Meyers JP, Jatoi A. Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ. 2013 Dec; 28 (4):770-6
    View PubMed
  106. Kaushik D, Kim SP, Childs MA, Lohse CM, Costello BA, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol. 2013 Oct; 64 (4):600-6 Epub 2012 Dec 25
    View PubMed
  107. Parikh SA, French CA, Costello BA, Marks RS, Dronca RS, Nerby CL, Roden AC, Peddareddigari VG, Hilton J, Shapiro GI, Molina JR. NUT midline carcinoma: an aggressive intrathoracic neoplasm. J Thorac Oncol. 2013 Oct; 8 (10):1335-8
    View PubMed
  108. Eisenberg MS, Cheville JC, Thompson RH, Kaushik D, Lohse CM, Boorjian SA, Costello BA, Leibovich BC. Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma. J Urol. 2013 Jul; 190 (1):37-43 Epub 2013 Jan 23
    View PubMed
  109. Marcelin JR, Jones JM, Costello BA. 41-year-old woman with fever, neutropenia, and elevated transaminase levels. Mayo Clin Proc. 2013 Jan; 88 (1):113-6
    View PubMed
  110. Kim SP, Crispen PL, Thompson RH, Weight CJ, Boorjian SA, Costello BA, Lohse CM, Leibovich BC. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma. Cancer. 2012 Sep 15; 118 (18):4412-20 Epub 2012 Jan 03
    View PubMed
  111. Kim SP, Thompson RH, Boorjian SA, Weight CJ, Han LC, Murad MH, Shippee ND, Erwin PJ, Costello BA, Chow GK, Leibovich BC. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012 Jul; 188 (1):51-7 Epub 2012 May 14
    View PubMed
  112. Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar; 87 (3):240-6
    View PubMed
  113. Kim SP, Shah ND, Weight CJ, Thompson RH, Moriarty JP, Shippee ND, Costello BA, Boorjian SA, Leibovich BC. Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol. 2011 Nov; 186 (5):1779-85 Epub 2011 Sept 25
    View PubMed
  114. Boorjian SA, Tollefson MK, Cheville JC, Costello BA, Thapa P, Frank I. Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival. J Urol. 2011 Nov; 186 (5):1796-802 Epub 2011 Sept 25
    View PubMed
  115. Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, Lohse CM, Boorjian SA. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011 Nov; 78 (5):1101-6 Epub 2011 Sept 08
    View PubMed
  116. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011 Jul 1; 117 (13):2873-82 Epub 2011 Jan 10
    View PubMed
  117. Kim SP, Alt AL, Weight CJ, Costello BA, Cheville JC, Lohse C, Allmer C, Leibovich BC. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol. 2011 Jun; 185 (6):2035-9 Epub 2011 Apr 15
    View PubMed
  118. Tilburt JC, James KM, Sinicrope PS, Eton DT, Costello BA, Carey J, Lane MA, Ehlers SL, Erwin PJ, Nowakowski KE, Murad MH. Factors influencing cancer risk perception in high risk populations: a systematic review. Hered Cancer Clin Pract. 2011 May 19; 9:2
    View PubMed
  119. Kim SP, Shah ND, Weight CJ, Thompson RH, Moriarty JP, Shippee ND, Costello BA, Boorjian SA, Leibovich BC. Contemporary trends in nephrectomy for renal cell carcinoma in the United States: Results from a population based cohort. International Braz J Urol. 2011; 37(5):663.
  120. McLeod TG, Costello BA, Colligan RC, Dierkhising RA, Beebe TJ, Offord KP, Locke GR 3rd. Personality characteristics of health care satisfaction survey non-respondents. Int J Health Care Qual Assur. 2009; 22 (2):145-56
    View PubMed
  121. Costello BA, McLeod TG, Locke GR 3rd, Dierkhising RA, Offord KP, Colligan RC. Pessimism and hostility scores as predictors of patient satisfaction ratings by medical out-patients. Int J Health Care Qual Assur. 2008; 21 (1):39-49
    View PubMed
  122. Sharma S, Tleyjeh IM, Espinosa RE, Costello BA, Baddour LM. Pacemaker infection due to Mycobacterium fortuitum. Scand J Infect Dis. 2005; 37(1):66-7.
    View PubMed
  123. Sood V, Costello BA, Burge MR. How low can you go? Chronic hypoglycemia versus normal glucose homeostasis. J Investig Med. 2001 Mar; 49(2):205-9.
    View PubMed
  124. Costello BA, Roberts F. Medical recommendations as joint social practice. Health Commun. 2001; 13(3):241-60.
    View PubMed